MedTrace Logo

An Open-Label PET/CT Imaging Study to Evaluate Brain Serotonin Transporter (SERT) Occupancy Following Single-Dose Administration of LG-0317 Tablets in Healthy Participants

NCT07708428 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-07-16

No results posted yet for this study

Summary

The purpose of the study is to evaluate brain serotonin transporter (SERT) receptor occupancy (RO) following single oral doses of LG-0317 tablets in healthy male participants; and to explore the pharmacokinetic/pharmacodynamic (PK/PD) relationship between LG-0317 plasma concentrations and SERT occupancy..

Conditions

  • Healthy Volunteers (HV)

Interventions

DRUG

Cohort 1: LG-0317 20 mg

Subjects will receive single dose of LG-0317 tablets.

DRUG

Cohort 1: LG-0317 40 mg

Subjects will receive single dose of LG-0317 tablets.

DRUG

Cohort 1: LG-0317 80 mg

Subjects will receive single dose of LG-0317 tablets.

Sponsors & Collaborators

  • LinGang Laboratory

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-24
Primary Completion
2026-09-30
Completion
2027-02-02

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07708428 on ClinicalTrials.gov